Y MAbs Company Insiders

YMAB Stock  USD 5.56  0.14  2.58%   
Y MAbs' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Y mAbs Therapeutics suggests that all insiders are panicking. Y MAbs employs about 100 people. The company is managed by 13 executives with a total tenure of roughly 18 years, averaging almost 1.0 years of service per executive, having 7.69 employees per reported executive.
Thomas Gad  Chairman
Chairman of the Board and Presidentident, Founder, Head of Business Development and Strategy
Joris Wilms  President
COO, Senior Vice President

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2024-09-16Thomas GadDisposed 30000 @ 12.97View
2024-09-13Thomas GadDisposed 65000 @ 13.47View
2024-08-26Joris WilmsDisposed 5000 @ 14.69View
2024-06-10Thomas GadDisposed 35000 @ 12.03View
2024-05-31Bo KruseDisposed 31371 @ 12.07View
2024-05-23Thomas GadDisposed 7351 @ 13View
2024-05-21Thomas GadDisposed 25000 @ 12View
2024-03-05Vignesh RajahDisposed 1711 @ 16.53View
Monitoring Y MAbs' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Y MAbs' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Y MAbs' future performance. Based on our forecasts, it is anticipated that YMAB will maintain a workforce of about 100 employees by April 2025.
 
Covid

Y MAbs Management Team Effectiveness

The company has return on total asset (ROA) of (0.1198) % which means that it has lost $0.1198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2478) %, meaning that it created substantial loss on money invested by shareholders. Y MAbs' management efficiency ratios could be used to measure how well Y MAbs manages its routine affairs as well as how well it operates its assets and liabilities. As of March 3, 2025, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Y MAbs' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 129.5 M, whereas Other Current Assets are forecasted to decline to about 4.9 M.
As of March 3, 2025, Common Stock Shares Outstanding is expected to decline to about 41.4 M. In addition to that, Net Loss is expected to decline to about (90.3 M)

Y MAbs Workforce Comparison

Y mAbs Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,676. Y MAbs holds roughly 100.0 in number of employees claiming about 2.72% of equities under Health Care industry.

Y MAbs Profit Margins

The company has Profit Margin (PM) of (0.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.43) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.43.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.981.0
Fairly Down
Slightly volatile

Y MAbs Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Y MAbs insiders, such as employees or executives, is commonly permitted as long as it does not rely on Y MAbs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Y MAbs insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
0.6667
4
6
 288,831 
 222,831 
2024-06-01
1.5556
14
9
 168,240 
 223,073 
2024-03-01
6.3333
19
3
 885,560 
 7,293 
2023-12-01
2.8333
17
6
 1,298,296 
 350,000 
2022-03-01
0.1
2
20
 16,000 
 806,288 
2021-12-01
0.5
10
20
 727,000 
 297,607 
2021-09-01
0.1176
2
17
 51,374 
 173,000 
2021-06-01
0.2903
9
31
 119,000 
 684,000 
2021-03-01
0.381
8
21
 1,075,927 
 1,147,927 
2020-12-01
0.75
15
20
 562,297 
 314,000 
2020-09-01
0.2143
3
14
 50,000 
 174,000 
2020-06-01
0.5
9
18
 204,000 
 530,000 
2020-03-01
0.4
6
15
 562,678 
 169,778 
2019-12-01
0.5556
5
9
 1,126,784 
 530,593 
2019-06-01
0.75
6
8
 96,000 
 274,000 
2018-12-01
3.0
6
2
 486,500 
 52,000 
2018-09-01
0.125
3
24
 945,799 
 2,077,000 

Y MAbs Notable Stakeholders

A Y MAbs stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Y MAbs often face trade-offs trying to please all of them. Y MAbs' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Y MAbs' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael RossiPresident CEOProfile
Thomas GadChairman of the Board and Presidentident, Founder, Head of Business Development and StrategyProfile
Joris WilmsCOO, Senior Vice PresidentProfile
Peter CPACFO TreasurerProfile
Bo KruseCFO, Treasurer, Secretary, DirectorProfile
MBBS MBASenior OfficerProfile
Sue SmithVP OfficerProfile
Doug GentilcoreSenior UnitProfile
FACNP FACPChief OfficerProfile
Courtney DuganVice RelationsProfile
Susan SmithSenior OfficerProfile
Torben MScVP OperationsProfile
MSc MDSenior OfficerProfile

About Y MAbs Management Performance

The success or failure of an entity such as Y mAbs Therapeutics often depends on how effective the management is. Y MAbs management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of YMAB management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the YMAB management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.15)(0.16)
Return On Capital Employed(0.21)(0.23)
Return On Assets(0.15)(0.16)
Return On Equity(0.19)(0.20)
Please note, the presentation of Y MAbs' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Y MAbs' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Y MAbs' management manipulating its earnings.

Y MAbs Workforce Analysis

Traditionally, organizations such as Y MAbs use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Y MAbs within its industry.

Y MAbs Manpower Efficiency

Return on Y MAbs Manpower

Revenue Per Employee848.2K
Revenue Per Executive6.5M
Net Loss Per Employee214.3K
Net Loss Per Executive1.6M
Working Capital Per Employee909.8K
Working Capital Per Executive7M

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
CEOs Directory
Screen CEOs from public companies around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation